Beauty Health (DE:V7A0)
FRANKFURT:V7A0
V7A0 Stock Chart & Stats
€0.76
-€0.09(-5.00%)
At close: 4:00 PM EST
€0.76
-€0.09(-5.00%)
Day’s Range― - ―
52-Week Range€0.48 - €2.20
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€76.55M
Enterprise Value€247.03M
Total Cash (Recent Filing)€204.40M
Total Debt (Recent Filing)€367.20M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 11, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding129,600,040
10 Day Avg. Volume0
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.88
Price to Sales (P/S)0.58
P/FCF Ratio4.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.16Price Target Upside52.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.13
Revenue Forecast (FY)€248.77M
Bulls Say, Bears Say
Bulls Say
High Product-level Margins And Positive FCFBeauty Health exhibits durable product-level economics: gross margins near 65%, mid-teens EBITDA margin, and positive trailing free cash flow (~$28.6M). Those characteristics support reinvestment in product innovation and organic growth while enabling gradual debt paydown if maintained.
Large Installed Base With Improving RetentionA 36,400-system installed base and a 40% reduction in churn materially strengthen recurring consumables demand and revenue visibility. High installed penetration creates network effects with providers, stabilizes service and consumable sales, and lengthens customer lifetime value.
Recurring Razor-and-blades Revenue ModelThe core razor-and-blades model aligns capital equipment placements with high-margin, repeat consumable sales per treatment. This structural revenue mix supports predictable, annuity-like cash flow as utilization rises, insulating the business from single-period device sales volatility.
Bears Say
Very High LeverageThe balance sheet's heavy leverage (~6.7x debt/equity and ~$367M debt) constrains strategic flexibility, raises refinancing and interest risks, and limits the company's ability to invest or absorb operating setbacks. Deleveraging will be slow unless cash generation meaningfully accelerates.
Top-line Weakness And Device Placement SoftnessSustained revenue declines and fewer device placements signal weaker demand for capital equipment. Structural headwinds—tighter credit, longer purchasing cycles, competition and a maturing market—mean equipment-led growth may remain constrained, delaying full realization of consumable revenue leverage.
Nasdaq Bid-price Noncompliance And Listing RiskA formal Nasdaq deficiency notice creates persistent listing risk and may force remedial actions (reverse split, appeal) that distract management, reduce equity financing options, and potentially weaken customer or partner confidence—a structural governance and capital-access vulnerability.
Beauty Health News
V7A0 FAQ
What was Beauty Health’s price range in the past 12 months?
Beauty Health lowest stock price was €0.48 and its highest was €2.20 in the past 12 months.
What is Beauty Health’s market cap?
Beauty Health’s market cap is €76.55M.
When is Beauty Health’s upcoming earnings report date?
Beauty Health’s upcoming earnings report date is Aug 11, 2026 which is in 47 days.
How were Beauty Health’s earnings last quarter?
Beauty Health released its earnings results on May 07, 2026. The company reported -€0.043 earnings per share for the quarter, beating the consensus estimate of -€0.064 by €0.021.
Is Beauty Health overvalued?
According to Wall Street analysts Beauty Health’s price is currently Undervalued.
Does Beauty Health pay dividends?
Beauty Health does not currently pay dividends.
What is Beauty Health’s EPS estimate?
Beauty Health’s EPS estimate is -0.02.
How many shares outstanding does Beauty Health have?
Beauty Health has 129,600,040 shares outstanding.
What happened to Beauty Health’s price movement after its last earnings report?
Beauty Health reported an EPS of -€0.043 in its last earnings report, beating expectations of -€0.064. Following the earnings report the stock price went down -36.424%.
Which hedge fund is a major shareholder of Beauty Health?
Currently, no hedge funds are holding shares in DE:V7A0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beauty Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.16 (52.93% Upside)
€1.16 (52.93% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.85%
12-Months-Change
Fundamentals
Return on Equity
-9.41%
Trailing 12-Months
Asset Growth
-29.77%
Trailing 12-Months
Company Description
Beauty Health
The Beauty Health Company is an international enterprise focused on the conceptualization, development, production, promotion, and distribution of advanced aesthetic equipment and beauty solutions. Its leading offering is HydraFacial, a renowned skincare system that works to revitalize the complexion through a multi-step process: deep cleansing, gentle exfoliation, impurity extraction, active ingredient infusion, and intensive hydration, all powered by proprietary blends and specialized serums. Beyond this, their portfolio encompasses Syndeo, a sophisticated HydraFacial Delivery System designed to optimize every phase of the treatment and allow practitioners to tailor experiences to individual client preferences. They also provide the HydraFacial Nation App, a digital tool enabling users to gain insights into their skin's condition, explore various treatment options, and track their progress over subsequent sessions. Another key product is Keravive, a specialized treatment dedicated to fostering scalp health. The company was established in 1997 and maintains its corporate headquarters in Long Beach, California.
V7A0 Company Deck
V7A0 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: operational and financial discipline produced a notable EBITDA beat, margin expansion, improved installed base metrics, and strong liquidity, but top-line performance remains pressured with declining sales, softer device placements, and structural macro/competitive headwinds. Management is taking concrete commercial and product actions and maintained EBITDA guidance while trimming revenue expectations, positioning 2026 as an execution/stabilization year with recovery expected in 2027.View all DE:V7A0 earnings summariesV7A0 Stock 12 Month Forecast
Average Price Target
€1.16
▲(52.93% Upside)
Technical Analysis
Options Prices
Currently, No data available
---